CA2402596A1 - Anticorps de facteur anti-tissulaire a pouvoir anticoagulant ameliore - Google Patents

Anticorps de facteur anti-tissulaire a pouvoir anticoagulant ameliore Download PDF

Info

Publication number
CA2402596A1
CA2402596A1 CA002402596A CA2402596A CA2402596A1 CA 2402596 A1 CA2402596 A1 CA 2402596A1 CA 002402596 A CA002402596 A CA 002402596A CA 2402596 A CA2402596 A CA 2402596A CA 2402596 A1 CA2402596 A1 CA 2402596A1
Authority
CA
Canada
Prior art keywords
antibody
antibodies
seq
sequence
fviia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002402596A
Other languages
English (en)
Inventor
Daniel K. Kirchhofer
David G. Lowe
Leonard G. Presta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2402596A1 publication Critical patent/CA2402596A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Abstract

L'invention concerne des anticorps de facteur anti-tissulaire (anti-TF) à pouvoir anticoagulant amélioré, ainsi que des procédés et des moyens d'identification, de production et d'utilisation de tels anticorps. Ces anticorps anti-TF sont conçus afin de contenir une région de liaison à un épitope situé dans la région de liaison de substrat macromoléculaire C-terminale de TF.
CA002402596A 2000-03-16 2001-03-08 Anticorps de facteur anti-tissulaire a pouvoir anticoagulant ameliore Abandoned CA2402596A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18977500P 2000-03-16 2000-03-16
US60/189,775 2000-03-16
PCT/US2001/007501 WO2001070984A2 (fr) 2000-03-16 2001-03-08 Anticorps de facteur anti-tissulaire a pouvoir anticoagulant ameliore

Publications (1)

Publication Number Publication Date
CA2402596A1 true CA2402596A1 (fr) 2001-09-27

Family

ID=22698717

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002402596A Abandoned CA2402596A1 (fr) 2000-03-16 2001-03-08 Anticorps de facteur anti-tissulaire a pouvoir anticoagulant ameliore

Country Status (6)

Country Link
EP (1) EP1263960A2 (fr)
JP (1) JP2003527861A (fr)
AU (2) AU2001250814B2 (fr)
CA (1) CA2402596A1 (fr)
HK (1) HK1049184A1 (fr)
WO (1) WO2001070984A2 (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0833911T3 (da) 1995-06-07 2004-08-30 Ortho Mcneil Pharm Inc CDR-transplanterede anti-vævsfaktorantistoffer og fremgangsmåder til anvendelse deraf
US7749498B2 (en) 1997-03-10 2010-07-06 Genentech, Inc. Antibodies for inhibiting blood coagulation and methods of use thereof
US20060235209A9 (en) 1997-03-10 2006-10-19 Jin-An Jiao Use of anti-tissue factor antibodies for treating thromboses
US20030109680A1 (en) 2001-11-21 2003-06-12 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
US5986065A (en) 1997-03-10 1999-11-16 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
US6703494B2 (en) 2000-03-16 2004-03-09 Genentech, Inc. Anti-tissue factor antibodies with enhanced anticoagulant potency
WO2002078738A1 (fr) * 2001-03-26 2002-10-10 Koji Suzuki Agents ameliorant la rheologie sanguine
CN1575302A (zh) * 2001-10-02 2005-02-02 诺沃挪第克公司 人组织因子抗体
TWI338009B (en) * 2001-10-29 2011-03-01 Genentech Inc Antibodies for inhibiting blood coagulation and methods of use thereof
AU2003206571A1 (en) * 2002-02-22 2003-09-09 Prophy Med Ab Use of an inhibitor or antagonist against tissue factor
JP4460443B2 (ja) * 2002-05-01 2010-05-12 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト 抗凝固剤としての新規組織因子標的化された抗体
US7579000B2 (en) 2002-05-01 2009-08-25 Bayer Schering Pharma Ag Tissue factor targeted antibodies as anticoagulants
AU2003277832A1 (en) * 2002-10-31 2004-05-25 Novo Nordisk A/S Humanized tissue factor antibodies
WO2004041302A1 (fr) * 2002-11-06 2004-05-21 Novo Nordisk A/S Composition pharmaceutique comprenant un antagoniste de facteur tissulaire et un regulateur de glycemie
CA2513113A1 (fr) 2003-01-23 2004-08-05 Genentech, Inc. Procedes de production d'anticoprs humanises et d'amelioration du rendement d'anticorps ou de fragments de liaison d'antigenes en culture cellulaire
JP2006517109A (ja) * 2003-02-07 2006-07-20 プロテイン デザイン ラブス インコーポレイテッド アンフィレグリン抗体ならびに癌および乾癬を処置するためのその使用
WO2004075913A1 (fr) 2003-02-28 2004-09-10 Chugai Seiyaku Kabushiki Kaisha Preparation stabilisee contenant une proteine
US7425328B2 (en) 2003-04-22 2008-09-16 Purdue Pharma L.P. Tissue factor antibodies and uses thereof
EP1633309A4 (fr) * 2003-05-30 2007-06-13 Centocor Inc Procede pour inhiber la croissance tumorale avec des anticorps a facteurs anti-tissulaires
AU2004251161A1 (en) * 2003-05-30 2005-01-06 Genentech, Inc. Polypeptides that bind an anti-tissue factor antibody and uses thereof
US7605235B2 (en) 2003-05-30 2009-10-20 Centocor, Inc. Anti-tissue factor antibodies and compositions
US9708410B2 (en) 2003-05-30 2017-07-18 Janssen Biotech, Inc. Anti-tissue factor antibodies and compositions
WO2005004793A2 (fr) * 2003-06-19 2005-01-20 Tanox Inc. Compositions et procedes pour le traitement des troubles lies a la coagulation
ITRM20030601A1 (it) * 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
BRPI0610470A2 (pt) 2005-05-26 2010-06-22 Seattle Genetics Inc anticorpo isolado ou fragmento de ligação a antìgeno que especificamente se liga a cd40 humano, kit, composição farmacêutica, e, polinucleotìdeo isolado
ITRM20050290A1 (it) 2005-06-07 2006-12-08 Lay Line Genomics Spa Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
EP2993186B1 (fr) 2008-03-14 2019-09-04 Biocon Limited Anticorps monoclonal et procédé associé
UA109633C2 (uk) 2008-12-09 2015-09-25 Антитіло людини проти тканинного фактора
CN106084053B (zh) 2010-06-15 2020-01-17 根马布股份公司 针对组织因子的人抗体药物缀合物
US8722044B2 (en) 2011-03-15 2014-05-13 Janssen Biotech, Inc. Human tissue factor antibody and uses thereof
CN105229023B (zh) 2013-03-15 2019-08-16 加利福尼亚大学董事会 源自线粒体的肽mots3调节代谢和细胞存活
NZ746944A (en) 2013-07-23 2021-07-30 Biocon Ltd Use of a cd6 binding partner and method based thereon
EP3103811A4 (fr) * 2014-02-03 2017-11-29 National Cancer Center Anticorps monoclonal anti-facteur tissulaire
CA3039855A1 (fr) 2016-10-21 2018-04-26 Biocon Limited Anticorps monoclonal et procede d'utilisation pour le traitement du lupus
TW201922796A (zh) * 2017-10-30 2019-06-16 國立研究開發法人國立癌症研究中心 可用於實體腫瘤治療之抗體及其抗體－藥物共軛物以及含其之抗癌劑
KR20230037042A (ko) * 2020-07-10 2023-03-15 아이코닉 테라퓨틱스, 인코포레이티드 항조직 인자 항체를 사용하는 염증성 질환 치료

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US596065A (en) * 1897-12-28 Ejector for ashes
DE3237880A1 (de) * 1982-10-13 1984-04-19 Robert Bosch Gmbh, 7000 Stuttgart Kodierspeicher, insbesondere fuer werkstuecktraeger in der fliessfertigung
JPS60188045A (ja) * 1984-03-08 1985-09-25 リサーチ・コーポレイシヨン 保存安定性魚肉ベース製品
US5811248A (en) * 1986-03-31 1998-09-22 Charter Ventures Atherosclerotic plaque specific antigens, antibodies thereto, and uses thereof
US5986065A (en) * 1997-03-10 1999-11-16 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
ES2364266T3 (es) * 1998-04-03 2011-08-30 Chugai Seiyaku Kabushiki Kaisha Anticuerpo humanizado hacia el factor tisular humano (tf) y procedimiento para construir el anticuerpo humanizado.

Also Published As

Publication number Publication date
JP2003527861A (ja) 2003-09-24
AU2001250814B2 (en) 2007-02-15
HK1049184A1 (zh) 2003-05-02
WO2001070984A3 (fr) 2002-02-28
AU5081401A (en) 2001-10-03
WO2001070984A2 (fr) 2001-09-27
EP1263960A2 (fr) 2002-12-11

Similar Documents

Publication Publication Date Title
AU2001250814B2 (en) Anti-tissue factor antibodies with enhanced anticoagulant potency
US7435413B2 (en) Anti-tissue factor antibodies with enhanced anticoagulant potency
AU2001250814A1 (en) Anti-tissue factor antibodies with enhanced anticoagulant potency
EP2297207B1 (fr) Utilisation d anticorps anti-facteurs xi pour prévenir la formation de thrombus
AU706397B2 (en) Anticoagulant agents useful in treatment of thrombosis
RU2474589C9 (ru) Гуманизированные антитела к фактору d и их применения
US20190106509A1 (en) Monoclonal antibodies against the active site of factor XI and uses thereof
US20160297892A1 (en) Novel Methods and Antibodies for Treating Coagulapathy
TW201802120A (zh) 抗凝血因子ｘｉ抗體
US20060057140A1 (en) Anticoagulant agents useful in treatment of thrombosis
US20030124117A1 (en) Combinations of anti-tissue factor antibodies and anticoagulant and/or antiplatelet agents
US20040146511A1 (en) Antithrombotic agents
US20030143225A1 (en) Combinations of anti-tissue factor antibodies and anticoagulant and/or antiplatelet agents
JP2004516236A (ja) 抗血栓剤
US20070190059A1 (en) Antithrombotic agents

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead